X4 Pharmaceuticals, Inc. (XFOR) Stock Grade

About X4 Pharmaceuticals, Inc.'s fundamentals

X4 Pharmaceuticals is a biotechnology company with a market capitalization of $169.2 million that reported exceptional revenue growth of 1,273% year-over-year, indicating rapid commercialization of its products. However, the company operates at a significant loss, with a net margin of -225.6%, meaning it spent substantially more than it earned in its latest annual period. The company does not pay a dividend and lacks positive earnings, which is typical for early-stage biotech firms scaling operations but relevant for investors evaluating profitability timelines.